Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, and thank you for joining Zevra's Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call.
Zevra Therapeutics Inc. (ZVRA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Woodline Partners Michael Rockefeller And Karl Kroeker | 4,139,593 | $34,524,206 | +3% | 0.23% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 3,650,000 | $30,441,000 | +463% | 0.05% |
| 3. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,340,333 | $19,518,377 | -20% | 0.83% |
| 4. | Altium Capital Jacob Gottlieb | 1,850,000 | $15,429,000 | +9% | 4.37% |
| 5. | 683 Capital Partners Ari Zweiman | 1,225,834 | $10,223,455 | +1% | 0.63% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.84 | 300 | Director | 1,800 | 2025-03-28 | Filing | |
| $7.96 | 10,000 | Director | 40,000 | 2025-03-19 | Filing | |
| $7.92 | 500 | Director | 1,500 | 2024-10-11 | Filing | |
| $6.77 | 2,000 | Officer | 18,469 | 2024-07-17 | Filing | |
| $6.81 | 10,000 | Director | 20,000 | 2024-07-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.86 | 3,000 | Officer | 16,341 | 2025-02-13 | Filing | |
| $7.86 | 10,500 | Officer | 29,486 | 2025-02-13 | Filing | |
| $7.86 | 11,000 | Officer | 51,361 | 2025-02-13 | Filing | |
| $8.05 | 30,544 | Officer, Director | 191,516 | 2025-02-14 | Filing | |
| $7.86 | 61,273 | Officer, Director | 222,060 | 2025-02-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 74,585 | $558,630 | 0% | |
| 2. | 29,050 | $217,585 | 0.04% | |
| 3. | 16,224 | $121,518 | 0.04% | |
| 4. | 150 | $1,124 | 0% | |
| 5. | 8,059 | $1,076 | 0.01% |
News See All
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and thank you for joining Zevra Therapeutics Third Quarter Financial Results and Corporate Update Conference Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2024 Earnings Call Transcript
Operator: Hello, and thank you for joining the Zevra Therapeutics Q2 2024 Financial Results and Corporate Highlights Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript
Operator: Good morning, everyone. Thank you for joining the Zevra Therapeutics' First Quarter 2024 Corporate Update and Financial Results Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript
Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.2.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2023 Earnings Call Transcript
Operator: Good morning, everyone. Thank you for joining the Zevra Therapeutics Third Quarter 2023 Corporate Updates and Financial Results Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Zevra Therapeutics Second Quarter 2023 Corporate and Financial Results Conference Call.
Billionaire Hedge Funds
